Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache.

Kopruszinski CM, Navratilova E, Vagnerova B, Swiokla J, Patwardhan A, Dodick D, Porreca F.

Cephalalgia. 2020 Jan;40(1):68-78. doi: 10.1177/0333102419865252. Epub 2019 Jul 16.

PMID:
31311288
2.

Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.

Suplita RL 2nd, Eisenstein SA, Neely MH, Moise AM, Hohmann AG.

Neuropharmacology. 2008 Jan;54(1):161-71. Epub 2007 Jul 19.

3.

Triptan-induced latent sensitization: a possible basis for medication overuse headache.

De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I, Dodick DW, Vanderah TW, Dussor G, Porreca F.

Ann Neurol. 2010 Mar;67(3):325-37. doi: 10.1002/ana.21897.

5.

Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine.

Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G.

Psychopharmacology (Berl). 2001 Nov;158(3):259-66.

PMID:
11713615
6.

CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice.

Navratilova E, Rau J, Oyarzo J, Tien J, Mackenzie K, Stratton J, Remeniuk B, Schwedt T, Anderson T, Dodick D, Porreca F.

Cephalalgia. 2019 Dec;39(14):1762-1775. doi: 10.1177/0333102419877662. Epub 2019 Sep 24.

PMID:
31550910
7.

A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part II: comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents.

Manwell LA, Ford B, Matthews BA, Heipel H, Mallet PE.

J Pharmacol Toxicol Methods. 2014 Jul-Aug;70(1):112-9. doi: 10.1016/j.vascn.2014.06.004. Epub 2014 Jun 21.

PMID:
24956154
8.

Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.

Scherma M, Dessì C, Muntoni AL, Lecca S, Satta V, Luchicchi A, Pistis M, Panlilio LV, Fattore L, Goldberg SR, Fratta W, Fadda P.

Neuropsychopharmacology. 2016 Apr;41(5):1416-26. doi: 10.1038/npp.2015.295. Epub 2015 Sep 21.

9.

Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.

Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J, Bigal M, Chichorro JG, Dodick D, Porreca F.

Cephalalgia. 2017 May;37(6):560-570. doi: 10.1177/0333102416650702. Epub 2016 May 19.

PMID:
27206958
10.

Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.

Wiley JL, Compton DR, Gordon PM, Siegel C, Singer M, Dutta A, Lichtman AH, Balster RL, Razdan RK, Martin BR.

Neuropharmacology. 1996;35(12):1793-804.

PMID:
9076759
11.
12.

Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache.

Green AL, Gu P, De Felice M, Dodick D, Ossipov MH, Porreca F.

Cephalalgia. 2014 Jul;34(8):594-604. doi: 10.1177/0333102413515344. Epub 2013 Dec 11.

13.

Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Lefever TW, Marusich JA, Antonazzo KR, Wiley JL.

Pharmacol Biochem Behav. 2014 Mar;118:30-5. doi: 10.1016/j.pbb.2014.01.002. Epub 2014 Jan 9.

15.

Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.

DeLong GT, Wolf CE, Poklis A, Lichtman AH.

Drug Alcohol Depend. 2010 Nov 1;112(1-2):126-33. doi: 10.1016/j.drugalcdep.2010.05.019.

16.
17.

Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission.

Cadoni C, Valentini V, Di Chiara G.

J Neurochem. 2008 Aug;106(4):1586-93. doi: 10.1111/j.1471-4159.2008.05503.x. Epub 2008 Jun 28.

18.

Medication overuse headache following repeated morphine, but not [INCREMENT]9-tetrahydrocannabinol administration in the female rat.

Kandasamy R, Dawson CT, Hilgendorf TN, Morgan MM.

Behav Pharmacol. 2018 Aug;29(5):469-472. doi: 10.1097/FBP.0000000000000382.

19.

Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.

Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR.

Learn Mem. 2007 Jan 3;14(1-2):63-74. Print 2007 Jan-Feb.

20.

Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.

Araya KA, David Pessoa Mahana C, González LG.

Eur J Pharmacol. 2007 Oct 15;572(1):32-9. Epub 2007 Jun 21.

PMID:
17644088

Supplemental Content

Support Center